Publications

  1. Ailawadhi S, Cheng M, Cherepanov D, DerSarkissian M, Stull DM, Hilts A, Chun J, Duh MS, Sanchez L. Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data. Curr Probl Cancer. 2024 Jun; 50:101078 Epub 2024 Mar 27
    View PubMed
  2. Quach H, Parmar G, Mateos MV, Ailawadhi S, Leleu X. Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024 Jun; 24 (6):358-363 Epub 2024 Feb 12
    View PubMed
  3. Ailawadhi S, Adu Y, Frank RD, Das S, Hodge DO, Fernandez A, Flott C, Elliott J, Parrondo R, Sher T, Roy V, Chanan-Khan AA. Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities. Blood Cancer J. 2024 May 28; 14 (1):86
    View PubMed
  4. Zanwar S, Le-Rademacher J, Durot E, D'Sa S, Abeykoon JP, Mondello P, Kumar S, Sarosiek S, Paludo J, Chhabra S, Cook JM, Parrondo R, Dispenzieri A, Gonsalves WI, Muchtar E, Ailawadhi S, Kyle RA, Rajkumar SV, Delmer A, Fonseca R, Gertz MA, Treon SP, Ansell SM, Castillo JJ, Kapoor P. Simplified Risk Stratification Model for Patients With Waldenstrom Macroglobulinemia. J Clin Oncol. 2024 May 24; JCO2302066 [Epub ahead of print]
    View PubMed
  5. Alodhaibi I, Ailawadhi S, Burbano GP, O'Brien PJ, Buadi FK, Hayman S, Kumar SK, Gonsalves WI. An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2024 May; 24 (5):298-304 Epub 2024 Jan 06
    View PubMed
  6. Chohan K, Paludo J, Dasari S, Mondello P, Novak JP, Abeykoon JP, Wenzl K, Yang ZZ, Jalali S, Krull JE, Braggio E, Manske MK, Paulus A, Reeder CB, Ailawadhi S, Chanan-Khan A, Kapoor P, Kyle RA, Gertz MA, Novak AJ, Ansell SM. MicroRNA and long non-coding RNA analysis in IgM-monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis. Haematologica 2024 May 1; 109 (5):1570-1575 Epub 2024 May 01
    View PubMed
  7. Ailawadhi S, Romanus D, Shah S, Fraeman K, Saragoussi D, Buus RM, Nguyen B, Cherepanov D, Lamerato L, Berger A. Development and validation of algorithms for identifying lines of therapy in multiple myeloma using real-world data. Future Oncol. 2024 May; 20 (15):981-995 Epub 2024 Jan 17
    View PubMed
  8. Ailawadhi S, Shune L, Wong SW, Lin Y, Patel K, Jagannath S. Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable. Clin Lymphoma Myeloma Leuk. 2024 May; 24 (5):e217-e225 Epub 2024 Feb 01
    View PubMed
  9. Parrondo RD, Dutta N, LaPlant BR, Elliott J, Fernandez A, Zimmerman A, Cicco G, Han B, Heslop K, Chapin D, Sher T, Roy V, Rasheed A, Das S, Chanan-Khan AA, Paulus A, Ailawadhi S. A phase II study of ibrutinib in combination with ixazomib in patients with Waldenstrom macroglobulinaemia. Br J Haematol. 2024 May; 204 (5):1825-1829 Epub 2024 Jan 29
    View PubMed
  10. Khera N, Ailawadhi S, Brazauskas R, Patel J, Jacobs B, Ustun C, Ballen K, Abid MB, Diaz MA, Al-Homsi AS, Hashem H, Hong S, Munker R, Schears R, Lazarus HM, Ciurea SO, Badawy SM, Savani BN, Wirk B, LeMaistre CF, Bhatt NS, Beitinjaneh A, Aljurf M, Sharma A, Cerny J, Knight JM, Kelkar AH, Yared JA, Kindwall-Keller T, Winestone LE, Steinberg A, Arnold SD, Seo S, Preussler JM, Hossain NM, Fingrut WB, Agrawal V, Hashmi S, Lehmann LE, Wood WA, Rangarajan HG, Saber W, Hahn T. Trends in Volumes and Survival After Hematopoietic Cell Transplantation in Racial/Ethnic Minorities. Blood Adv. 2024 Apr 25 [Epub ahead of print]
    View PubMed
  11. Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma. Future Oncol. 2024 Apr 23; 1-15 [Epub ahead of print]
    View PubMed
  12. Ballas L, Ailawadhi S, Narang M, Gasparetto CJ, Lee HC, Hardin JW, Durie BGM, Toomey K, Omel J, Wagner LI, Abonour R, Terebelo HR, Joshi P, Yu E, Liu L, Rifkin RM, Jagannath S. Real-World Utilization of Radiation Therapy in Multiple Myeloma: An Analysis of the Connect MM Registry. Pract Radiat Oncol. 2024 Mar-Apr; 14 (2):e141-e149 Epub 2023 Nov 19
    View PubMed
  13. Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodriguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial. Lancet Haematol. 2024 Mar; 11 (3):e216-e227
    View PubMed
  14. Nadeem O, Ailawadhi S, Khouri J, Williams L, Catamero D, Maples K, Berdeja J. Management of Adverse Events Associated with Pomalidomide-Based Combinations in Patients with Relapsed/Refractory Multiple Myeloma. Cancers (Basel). 2024 Feb 29; 16 (5)
    View PubMed
  15. Pang S, Saleh H, Ailawadhi S, Edgar M, Pang M. Acute esophageal stricture after bone marrow transplant. Clin J Gastroenterol. 2024 Feb; 17 (1):1-5 Epub 2023 Oct 27
    View PubMed
  16. Ailawadhi S, Ravelo A, Ng CD, Shah B, Lamarre N, Wang R, Eakle K, Biondo JM. Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA. J Comp Eff Res. 2024 Feb; 13 (2):e230119 Epub 2024 Jan 31
    View PubMed
  17. Gagnon MF, Midthun SM, Fangel JA, Schuh CM, Luoma IM, Pearce KE, Meyer RG, Ailawadhi S, Arribas MJ, Braggio E, Fonseca R, Rajkumar SV, Zepeda-Mendoza C, Xu X, Greipp PT, Timm MM, Otteson GE, Shi M, Jevremovic D, Olteanu H, Peterson JF, Ketterling RP, Kumar S, Baughn LB. Superior detection rate of plasma cell FISH using FACS-FISH. Am J Clin Pathol. 2024 Jan 4; 161 (1):60-70
    View PubMed
  18. Alhaj Moustafa M, Parrondo R, Abdulazeez MF, Roy V, Sher T, Alegria VR, Warsame RM, Fonseca R, Rasheed A, Gonsalves WI, Kourelis T, Kapoor P, Buadi FK, Dingli D, Hayman SR, Reeder CB, Chanan-Khan AA, Ailawadhi S. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma. Anticancer Drugs. 2024 Jan 1; 35 (1):63-69 Epub 2023 Apr 06
    View PubMed
  19. Parrondo RD, Ailawadhi S, Cerchione C. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives. Front Oncol. 2024; 14:1394048 Epub 2024 Apr 10
    View PubMed
  20. Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodriguez-Otero P. Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label karmma-3 clinical trial. The Lancet Haematology. 2024; 11 (3):e216-27
  21. Espinoza-Gutarra MR, Aiello J, Orlowski RZ, Ailawadhi S. Clinical trial design change implementation for inclusive studies. Lancet Haematol. 2023 Dec; 10 (12):e953-e954
    View PubMed
  22. Yadav U, Kumar SK, Baughn LB, Dispenzieri A, Greipp P, Ketterling R, Jevremovic D, Buadi FK, Dingli D, Lacy MQ, Fonseca R, Bergsagel PL, Ailawadhi S, Roy V, Parrondo R, Sher T, Hayman SR, Kapoor P, Leung N, Cook J, Binder M, Muchtar E, Warsame R, Kourelis TV, Go RS, Lin Y, Seth A, Lester SC, Breen WG, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. Blood. 2023 Nov 30; 142 (22):1871-1878
    View PubMed
  23. Sanchez L, Chari A, Cheng M, Cherepanov D, DerSarkissian M, Huang F, Stull DM, Dabora J, Young M, Noga SJ, Pi S, Zhang M, Banatwala A, Duh MS, Ailawadhi S. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States. J Manag Care Spec Pharm. 2023 Nov; 29 (11):1205-1218 Epub 2023 Sept 30
    View PubMed
  24. Das S, Ailawadhi S, Sher T, Roy V, Fernandez A, Parrondo RD. Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety. Curr Oncol. 2023 Oct 31; 30 (11):9627-9633
    View PubMed
  25. Beck K, Sandahl T, Ailawadhi S, Khera N, Jensen C. Multiple Myeloma: Current Clinical Landscape and Compounding Costs. Curr Hematol Malig Rep. 2023 Oct; 18 (5):201-215 Epub 2023 July 21
    View PubMed
  26. Yassine F, Kharfan-Dabaja MA, Tsalantsanis A, Roy V, Zubair AC, Murthy HS, Ayala E, Iqbal M, Sher T, Ailawadhi S, Parrondo RD. Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience. Bone Marrow Transplant. 2023 Oct; 58 (10):1130-1136 Epub 2023 July 21
    View PubMed
  27. Ailawadhi S, Ailawadhi M, Dutta N, Parrondo RD, Roy V, Sher T, Baksh M, Rasheed A, Das S, Fernandez AJ, Paulus A, Chanan-Khan AA. The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers. Cancer Med. 2023 Sep; 12 (18):19013-19020 Epub 2023 Aug 17
    View PubMed
  28. Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, Braunlein E, Cordas Dos Santos DM, Freeman CL, Alsina M, Theurich S, Wang Y, Krackhardt AM, Locke FL, Bachy E, Jain MD, Lin Y, Subklewe M. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J Hematol Oncol. 2023 Jul 31; 16 (1):88 Epub 2023 July 31
    View PubMed
  29. Mateos MV, Ailawadhi S, Costa LJ, Grant SJ, Kumar L, Mohty M, Aydin D, Usmani SZ. Global disparities in patients with multiple myeloma: a rapid evidence assessment. Blood Cancer J. 2023 Jul 18; 13 (1):109 Epub 2023 July 18
    View PubMed
  30. Ailawadhi S, Chen Z, Huang B, Paulus A, Collins MC, Fu LT, Li M, Ahmad M, Men L, Wang H, Davids MS, Liang E, Mekala DJ, He Z, Lasica M, Yannakou CK, Parrondo R, Glass L, Yang D, Chanan-Khan A, Zhai Y. Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial. Clin Cancer Res. 2023 Jul 5; 29 (13):2385-2393
    View PubMed
  31. Kharfan-Dabaja MA, Roy V, Murthy H, Fischer D, Mohty R, Greathouse A, Brown A, Moreno K, Godsey E, Higginbotham JM, Bartholomew A, Jackson A, Torres-Guzman RA, Forte AJ, Ailawadhi S, Dronca R, Maniaci M. Post-Autologous Hematopoietic Cell Transplant Care in the "Home Sweet Home" Setting: A Treatment Paradigm Shift. Hematol Oncol Stem Cell Ther. 2023 May 23; 16 (4):407-411
    View PubMed
  32. Cerchione C, Grant SJ, Ailawadhi S. Partnering With All Patients: Ensuring Shared Decision Making and Evidence-Based Management for Underrepresented Groups With Multiple Myeloma. Am Soc Clin Oncol Educ Book. 2023 May; 43:e390202
    View PubMed
  33. Bansal R, Baksh M, Larsen JT, Hathcock MA, Dingli D, Stewart AK, Kapoor P, Kourelis T, Hayman SR, Warsame RM, Fonseca R, Bergsagel PL, Ailawadhi S, Kumar SK, Lin Y. Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. Blood Cancer J. 2023 Apr 5; 13 (1):47 Epub 2023 Apr 05
    View PubMed
  34. Kourelis T, Bansal R, Berdeja J, Siegel D, Patel K, Mailankody S, Htut M, Shah N, Wong SW, Sidana S, Cowan AJ, Alsina M, Cohen A, Holstein SA, Bergsagel L, Ailawadhi S, Raje N, Dhakal B, Rossi A, Lin Y. Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience. Transplant Cell Ther. 2023 Apr; 29 (4):255-258 Epub 2023 Jan 18
    View PubMed
  35. Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, Manier S, Callander N, Costa LJ, Vij R, Bahlis NJ, Moreau P, Solomon SR, Delforge M, Berdeja J, Truppel-Hartmann A, Yang Z, Favre-Kontula L, Wu F, Piasecki J, Cook M, Giralt S. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023 Mar 16; 388 (11):1002-1014 Epub 2023 Feb 10
    View PubMed
  36. Mondello P, Paludo J, Novak JP, Wenzl K, Yang ZZ, Jalali S, Krull JE, Braggio E, Dasari S, Manske MK, Abeykoon JA, Sarangi V, Kapoor P, Paulus A, Reeder CB, Ailawadhi S, Chanan-Khan AA, Kyle RA, Gertz MA, Novak AJ, Ansell SM. Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies. Clin Cancer Res. 2023 Mar 1; 29 (5):957-970
    View PubMed
  37. Chohan KL, Paludo J, Vallumsetla N, Larson D, King RL, He R, Gonsalves W, Inwards D, Witzig TE, Swaika A, Jain T, Leung N, Ailawadhi S, Reeder CB, Lacy MQ, Rajkumar SV, Kumar S, Kyle RA, Gertz MA, Ansell SM, Kapoor P. Survival trends in young patients with Waldenstrom macroglobulinemia: Over five decades of experience. Am J Hematol. 2023 Mar; 98 (3):432-439 Epub 2023 Jan 01
    View PubMed
  38. Ailawadhi S, Ogbonnaya A, Murty S, Cherepanov D, Schroader BK, Romanus D, Farrelly E, Chari A. Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant. Cancer Med. 2023 Feb; 12 (3):3145-3159 Epub 2022 Sept 24
    View PubMed
  39. Lee HC, Ramasamy K, Weisel K, Abonour R, Hardin JW, Rifkin RM, Ailawadhi S, Terebelo HR, Durie BGM, Tang D, Joshi P, Liu L, Jou YM, Che M, Hernandez G, Narang M, Toomey K, Gasparetto C, Wagner LI, Jagannath S. Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry. Clin Lymphoma Myeloma Leuk. 2023 Feb; 23 (2):112-122 Epub 2022 Nov 23
    View PubMed
  40. Ailawadhi S, Parrondo RD, Dutta N, Han B, Ciccio G, Cherukuri Y, Alegria VR, LaPlant BR, Roy V, Sher T, Edwards B, Lanier S, Manna A, Heslop K, Caulfield T, Maldosevic E, Storz P, Manochakian R, Asmann Y, Chanan-Khan AA, Paulus A. AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma. Cancers (Basel). 2023 Jan 12; 15 (2)
    View PubMed
  41. Thomas C, Ailawadhi S, Popat R, Kleinman D, Ross MM, Gorsh B, Mulnick S, O'Neill A, Paka P, Hanna M, Krucien N, Molinari A, Gelhorn HL, Perera S. Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment. Front Med (Lausanne). 2023; 10:1271657 Epub 2023 Nov 23
    View PubMed
  42. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan A, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality In patients with COVID-19 in patients with multiple myeloma and AL amyloidosis. Am J Hematol. 2023 Jan; 98 (1):49-55 Epub 2022 Oct 24
    View PubMed
  43. Deng J, Paulus A, Fang DD, Manna A, Wang G, Wang H, Zhu S, Chen J, Min P, Yin Y, Dutta N, Halder N, Ciccio G, Copland JA, Miller J, Han B, Bai L, Liu L, Wang M, McEachern D, Przybranowski S, Yang CY, Stuckey JA, Wu D, Li C, Ryan J, Letai A, Ailawadhi S, Yang D, Wang S, Chanan-Khan A, Zhai Y. Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy. Clin Cancer Res. 2022 Dec 15; 28 (24):5455-5468
    View PubMed
  44. Chohan KL, Abeykoon JP, Ansell SM, Gertz MA, Kapoor P, Paulus A, Ailawadhi S, Reeder CB, Witzig TE, Habermann TM, Lacy MQ, Kyle RA, Go RS, Paludo J. Insurance-based disparities impact survival outcomes in Waldenstrom macroglobulinemia within the United States. Leuk Lymphoma. 2022 Dec; 63 (12):2879-2888 Epub 2022 July 23
    View PubMed
  45. Niazi SK, Iqbal M, Spaulding AC, Wood C, Manochakian R, Paulus A, Ailawadhi S, Brennan E, Kharfan Dabaja MA, Sher T. Impact of Benzodiazepine Use on Length of Stay and 30-Day ED Visits among Hospitalized Hematopoietic Stem Cell Transplant Recipients. South Med J. 2022 Dec; 115 (12):936-943
    View PubMed
  46. Ho M, Zanwar S, Buadi FK, Ailawadhi S, Larsen J, Bergsagel L, Binder M, Chanan-Khan AA, Dingli D, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves W, Go RS, Hayman S, Kapoor P, Kourelis T, Lacy MQ, Leung N, Lin Y, Muchtar E, Roy V, Sher T, Warsame R, Fonder A, Hobbs M, Hwa YL, Kyle RA, Rajkumar SV, Kumar S. Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance. Blood. 2022 Nov 3; 140 (18):1997-2000
    View PubMed
  47. Voleti SS, Warsame R, Mead-Harvey C, Ailawadhi S, Jain A, Fonseca R, Griffin JM, Khera N. Assessing Patient-Reported Financial Hardship in Patients With Cancer in Routine Clinical Care. JCO Oncol Pract. 2022 Nov; 18 (11):e1839-e1853 Epub 2022 Sept 27
    View PubMed
  48. Abeykoon JP, Vaxman J, Patel SV, Kumar S, Malave GC, Young KS, Ailawadhi S, Larsen JT, Dispenzieri A, Muchtar E, Gonsalves WI, Kourelis T, Leung N, Warsame R, Go RS, Bergsagel L, Lacy MQ, Rajkumar SV, Gertz MA, Kapoor P. Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma. Br J Haematol. 2022 Oct; 199(1):95-99. Epub 2022 Jun 13.
    View PubMed
  49. Ailawadhi S, Parrondo RD, Moustafa MA, LaPlant BR, Alegria V, Chapin D, Roy V, Sher T, Paulus A, Chanan-Khan AA. Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results. Hematol Oncol. 2022 Oct; 40 (4):695-703 Epub 2022 May 08
    View PubMed
  50. Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Chanan-Khan AA, Kenderian SS, Muchtar E, Wang Y, Ailawadhi S, Koehler AB, Parrondo R, Schwager SM, Sher T, Hanson CA, Shi M, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. Blood Cancer J. 2022 Sep 1; 12 (9):124 Epub 2022 Sept 01
    View PubMed
  51. Parrondo RD, Paulus A, Ailawadhi S. Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma. Cancers (Basel). 2022 Jul 8; 14 (14) Epub 2022 July 08
    View PubMed
  52. Raje N, Medhekar R, Panjabi S, Hines DM, Wang X, Iskander K, Welliver T, Wade RL, Ailawadhi S. Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients. J Oncol Pharm Pract. 2022 Jul; 28 (5):1130-1139 Epub 2021 June 10
    View PubMed
  53. Atrash S, Flahavan EM, Xu T, Ma E, Karve S, Hong WJ, Jirau-Lucca G, Nixon M, Ailawadhi S. Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis. Blood Cancer J. 2022 Mar 23; 12 (3):46
    View PubMed
  54. Gasparetto C, Jagannath S, Rifkin RM, Durie BGM, Narang M, Terebelo HR, Toomey K, Hardin JW, Wagner L, Ailawadhi S, Omel JL, Srinivasan S, Dhalla M, Catamero D, Kitali A, Agarwal A, Abonour R, Connect MM Registry Investigators. Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry. Clin Lymphoma Myeloma Leuk. 2022 Mar; 22 (3):149-157 Epub 2021 Aug 29
    View PubMed
  55. Ailawadhi S, Swaika A, Advani P, Hodge D, Paulus A, Khera N, Hashmi SK, Alegria VR, Abdulazeez M, Bodepudi S, Jamwal K, Roy V, Sher T, Chanan-Khan A, Ailawadhi M. Awareness of myeloma care and the global impact of treatment: An international internet-based prospective study. J Oncol Pharm Pract. 2022 Mar; 28 (2):425-433 Epub 2021 Mar 09
    View PubMed
  56. Baksh M, Li K, Jiang L, Alegria V, Sher T, Roy V, Chanan-Khan A, Ailawadhi S, Parrondo RD, Alhaj Moustafa M. Myelomatous ascites and pleural effusion in relapsed multiple myeloma. Clin Case Rep. 2022 Feb; 10 (2):e05329 Epub 2022 Feb 02
    View PubMed
  57. Bangerter LR, Looze M, Barry B, Harder K, Griffin J, Dezutter M, Khera N, Ailawadhi S, Schaepe K, Fischer K. A hybrid method of healthcare delivery research and human-centered design to develop technology-enabled support for caregivers of hematopoietic stem cell transplant recipients. Support Care Cancer. 2022 Jan; 30 (1):227-235 Epub 2021 July 13
    View PubMed
  58. Schwartzberg L, Broder MS, Ailawadhi S, Beltran H, Blakely LJ, Budd GT, Carr L, Cecchini M, Cobb P, Kansal A, Kim A, Monk BJ, Wong DJ, Campos C, Yermilov I. Impact of early detection on cancer curability: A modified Delphi panel study. PLoS One. 2022; 17 (12):e0279227 Epub 2022 Dec 21
    View PubMed
  59. Baksh M, Jiang L, Bhatia U, Alegria V, Sher T, Roy V, Chanan-Khan A, Ailawadhi S, Parrondo RD. Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature. Clin Case Rep. 2021 Dec; 9 (12):e05181 Epub 2021 Dec 07
    View PubMed
  60. Jayakrishnan T, Aulakh S, Baksh M, Nguyen K, Ailawadhi M, Samreen A, Parrondo R, Sher T, Roy V, Manochakian R, Paulus A, Chanan-Khan A, Ailawadhi S. Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting. Cancers (Basel). 2021 Nov 18; 13(22).
    View PubMed
  61. Kelly KR, Ailawadhi S, Siegel DS, Heffner LT, Somlo G, Jagannath S, Zimmerman TM, Munshi NC, Madan S, Chanan-Khan A, Lonial S, Chandwani S, Minasyan A, Ruehle M, Barmaki-Rad F, Abdolzade-Bavil A, Rharbaoui F, Herrmann-Keiner E, Haeder T, Wartenberg-Demand A, Anderson KC. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. Lancet Haematol. 2021 Nov; 8 (11):e794-e807 Epub 2021 Sept 13
    View PubMed
  62. Xie Z, Saliba AN, Abeykoon J, Majeed U, Almquist DR, Wiedmeier-Nutor JE, Bezerra E, Andrade-Gonzalez X, Hickman A, Sorenson K, Rakshit S, Wee C, Tella SH, Kommalapati A, Abdallah N, Pritchett J, De Andrade M, Uprety D, Badley A, Manochakian R, Ailawadhi S, Bryce AH, Hubbard JM, Gangat N, Thompson CA, Witzig TE, McWilliams RR, Leventakos K, Halfdanarson TR. Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies. JCO Oncol Pract. 2021 Sep; 17 (9):e1382-e1393 Epub 2021 June 14
    View PubMed
  63. Abeykoon JP, Zanwar S, Ansell SM, Muchtar E, He R, Greipp PT, King RL, Ailawadhi S, Paludo J, Larsen JT, Habermann TM, Inwards D, Go RS, Thanarajasingam G, Buadi F, Dispenzieri A, Thompson CA, Witzig TE, Lacy M, Gonsalves W, Nowakowski GS, Dingli D, Rajkumar SV, Kyle RA, Sher T, Roy V, Rosenthal A, Chanan-Khan AA, Reeder C, Gertz MA, Kumar S, Kapoor P. Assessment of fixed-duration therapies for treatment-naive Waldenstrom macroglobulinemia. Am J Hematol. 2021 Aug 1; 96 (8):945-953 Epub 2021 May 22
    View PubMed
  64. Muchtar E, Dispenzieri A, Gertz MA, Kumar SK, Buadi FK, Leung N, Lacy MQ, Dingli D, Ailawadhi S, Bergsagel PL, Fonseca R, Hayman SR, Kapoor P, Grogan M, Abou Ezzeddine OF, Rosenthal JL, Mauermann M, Siddiqui M, Gonsalves WI, Kourelis TV, Larsen JT, Reeder CB, Warsame R, Go RS, Murray DL, McPhail ED, Dasari S, Jevremovic D, Kyle RA, Lin Y, Lust JA, Russell SJ, Hwa YL, Fonder AL, Hobbs MA, Rajkumar SV, Roy V, Sher T. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. Mayo Clin Proc. 2021 Jun; 96(6):1546-1577.
    View PubMed
  65. Alhumaidi H, Manochakian R, Cochuyt J, Chindris A, Hodge D, Abdulazeez MF, David S, Biswas S, Aggarwal CS, Smallridge RC, Ailawadhi S. Initial treatment of patients with thyroid cancer: Outcomes and factors associated with care at academic versus nonacademic cancer centers. Cancer. 2021 Jun 1; 127 (11):1770-1778 Epub 2021 Jan 15
    View PubMed
  66. Kumar V, Ailawadhi M, Dutta N, Abdulazeez M, Aggarwal CS, Quintero G, Baksh M, Roy V, Sher T, Alegria V, Paulus A, Chanan-Khan A, Ailawadhi S. Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis. Clin Lymphoma Myeloma Leuk. 2021 May; 21 (5):e449-e455 Epub 2020 Dec 24
    View PubMed
  67. Parrondo RD, Moustafa MA, Reeder C, Sher T, Roy V, Muchtar E, Warsame R, Alegria V, Gonsalves W, Dingli D, Hayman S, Kapoor P, Chanan-Khan AA, Ailawadhi S. Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk. 2021 May; 21 (5):355-360 Epub 2021 Jan 12
    View PubMed
  68. Abonour R, Rifkin RM, Gasparetto C, Toomey K, Durie BGM, Hardin JW, Terebelo HR, Jagannath S, Narang M, Ailawadhi S, Omel JL, Lee HC, Srinivasan S, Kitali A, Agarwal A, Wagner L, CONNECT MM Registry Investigators. Effect of initial treatment on health-related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect((R)) MM Registry. Br J Haematol. 2021 Apr; 193 (1):93-100 Epub 2020 Oct 29
    View PubMed
  69. Niazi SK, Spaulding A, Brennan E, Meier SK, Crook JE, Cornell LF, Ailawadhi S, Clark MM, Rummans TA. Mental Health and Chemical Dependency Services at US Cancer Centers. J Natl Compr Canc Netw. 2021 Mar 4; 19 (7):829-838 Epub 2021 Mar 04
    View PubMed
  70. Ailawadhi S, Frank R, Ailawadhi M, Kanji Z, Jani P, Fiala M, Abdulazeez M, Ahmed S, Aggarwal CS, Aulakh S, Hodge D, Roy V, Alegria VR, Paulus A, Chanan-Khan A, Sher T. Utilization of radiation therapy in multiple myeloma: trends and changes in practice. Ann Hematol. 2021 Mar; 100 (3):735-741 Epub 2021 Jan 12
    View PubMed
  71. Gunaratne MDSK, Sahakian AJ, Abeykoon JP, Ansell SM, Gertz MA, Kapoor P, Paulus A, Ailawadhi S, Reeder CB, Witzig TE, Habermann TM, Novak AJ, Lacy MQ, Kyle RA, Go RS, Paludo J. Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2021 Feb; 62 (2):308-315 Epub 2020 Oct 15
    View PubMed
  72. Zhou K, Shi H, Chen R, Cochuyt JJ, Hodge DO, Manochakian R, Zhao Y, Ailawadhi S, Lou Y. Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer. JAMA Netw Open. 2021 Jan 4; 4 (1):e2032276 Epub 2021 Jan 04
    View PubMed
  73. Khokhar A, Spaulding A, Niazi Z, Ailawadhi S, Manochakian R, Chanan-Khan A, Niazi S, Sher T. A Panel Evaluation of the Changes in the General Public's Social-Media-Following of United States' Public Health Departments during COVID-19 Pandemic. J Prim Care Community Health. 2021 Jan-Dec; 12:2150132721995450
    View PubMed
  74. Sahu KK, Ailawadhi S, Malvik N, Cerny J. Challenges of Cellular Therapy During the COVID-19 Pandemic. Adv Exp Med Biol. 2021; 1318:657-672
    View PubMed
  75. Shi H, Zhou K, Cochuyt J, Hodge D, Qin H, Manochakian R, Zhao Y, Ailawadhi S, Adjei AA, Lou Y. Survival of Black and White Patients With Stage IV Small Cell Lung Cancer. Front Oncol. 2021; 11:773958 Epub 2021 Dec 10
    View PubMed
  76. Usmani SZ, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF, Valent J, Rosenzweig M, Zonder JA, Dhodapkar M, Callander N, Zimmerman T, Voorhees PM, Durie B, Rajkumar SV, Richardson PG, Orlowski RZ, SWOG1211 Trial Investigators. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. Lancet Haematol. 2021 Jan; 8 (1):e45-e54 Epub 2020 Dec 22
    View PubMed
  77. Yu Y, Brown Wade N, Hwang AE, Nooka AK, Fiala MA, Mohrbacher A, Peters ES, Pawlish K, Bock C, Van Den Berg DJ, Rand KA, Stram D, Conti DV, Auclair D, Colditz GA, Mehta J, Haiman CA, Terebelo H, Janakiraman N, Singhal S, Chiu B, Vij R, Bernal-Mizrachi L, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Cozen W, Ailawadhi S. Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. JCO Oncol Pract. 2020 Oct; 16 (10):e1169-e1180 Epub 2020 May 29
    View PubMed
  78. Jayakrishnan T, Bakalov V, Callander NS, Sadashiv S, Wagner R, Ailawadhi S. Impact of the Affordable Care Act on Timeliness to Treatment for Patients With Multiple Myeloma. Anticancer Res. 2020 Oct; 40 (10):5727-5734
    View PubMed
  79. Ailawadhi S, Jagannath S, Lee HC, Narang M, Rifkin RM, Terebelo HR, Durie BGM, Toomey K, Hardin JW, Gasparetto CJ, Wagner L, Omel JL, He M, Yue L, Flick ED, Agarwal A, Abonour R, Connect MM Registry Investigators. Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis. Cancer. 2020 Oct 1; 126 (19):4332-4340 Epub 2020 July 24
    View PubMed
  80. Dholaria B, Vanegas YAM, Diehl N, Spaulding AC, Visscher S, Tun HW, Ailawadhi S, Vishnu P. Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features. Clin Hematol Int. 2020 Sep; 2(3):117-124. Epub 2020 Apr 23.
    View PubMed
  81. Cornell L, Spaulding A, Vargas ,, Niazi S, Crook, Ailawadhi, Clark M, Rummans T, Meier S. Mental Health and Chemical Dependency Services at US Cancer Centers JNCCN. 2020.
  82. Ailawadhi S, Sexton R, Lentzsch S, Abidi MH, Voorhees PM, Cohen AD, Rohren EM, Heitner S, Kelly K, Mackler NJ, Baer DM, Hoering A, Durie B, Orlowski RZ. Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. Clin Cancer Res. 2020 Aug 1; 26 (15):3969-3978 Epub 2020 Apr 16
    View PubMed
  83. Iqbal M, Spaulding A, Niazi S, Wood C, Ahmed S, Jani P, Kharfan-Dabaja MA, Ayala E, Manochakian R, Ames S, Paulus A, Ailawadhi S, Roy V, Chanan-Khan A, Sher T. Impact of Depression and Anxiety on Opioid Use in Hospitalized Hematopoietic Cell Transplantation Recipients. Psychosomatics. 2020 Jul - Aug; 61 (4):363-370 Epub 2020 Mar 26
    View PubMed
  84. Ailawadhi S, Medhekar R, Princic N, Fowler R, Tran O, Bhowmik D, Panjabi S. Healthcare resource utilization and costs in patients with multiple myeloma with and without skeletal-related events. J Oncol Pharm Pract. 2020 Jul; 26 (5):1070-1079 Epub 2019 Oct 20
    View PubMed
  85. Manna A, Kellett T, Aulakh S, Lewis-Tuffin LJ, Dutta N, Knutson K, Chini E, Pinilla-Ibarz J, Lamanna N, Manochakian R, Malavasi F, Sher T, Chanan-Khan AA, Ailawadhi S, Paulus A. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses. Blood Adv. 2020 May 26; 4 (10):2143-2157
    View PubMed
  86. Jagannath S, Rifkin RM, Gasparetto CJ, Toomey K, Durie BGM, Hardin JW, Terebelo HR, Wagner L, Narang M, Ailawadhi S, Omel JL, Srinivasan S, He M, Ung B, Kitali A, Flick ED, Agarwal A, Abonour R, CONNECT MM Registry Investigators. Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry. Clin Lymphoma Myeloma Leuk. 2020 May; 20 (5):272-276 Epub 2019 Oct 14
    View PubMed
  87. Duma N, Idossa DW, Durani U, Frank RD, Paludo J, Westin G, Lou Y, Mansfield AS, Adjei AA, Go RS, Ailawadhi S. Influence of Sociodemographic Factors on Treatment Decisions in Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 May; 21 (3):e115-e129 Epub 2019 Aug 30
    View PubMed
  88. Chari A, Richardson PG, Romanus D, Dimopoulos MA, Sonneveld P, Terpos E, Hajek R, Raju A, Palumbo A, Cain LE, Blazer M, Huang H, Farrelly E, Ailawadhi S. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Rev Hematol. 2020 Apr; 13 (4):421-433 Epub 2020 Mar 09
    View PubMed
  89. Kumar V, Alhaj-Moustafa M, Bojanini L, Sher T, Roy V, Manochakian R, Vishnu P, Bodepudi S, Shareef Z, Ahmed S, Jani P, Paulus A, Grover A, Alegria VR, Ailawadhi M, Chanan-Khan A, Ailawadhi S. Timeliness of Initial Therapy in Multiple Myeloma: Trends and Factors Affecting Patient Care. JCO Oncol Pract. 2020 Apr; 16 (4):e341-e349 Epub 2020 Jan 21
    View PubMed
  90. Siddiqi T, Frankel P, Beumer JH, Kiesel BF, Christner S, Ruel C, Song JY, Chen R, Kelly KR, Ailawadhi S, Kaesberg P, Popplewell L, Puverel S, Piekarz R, Forman SJ, Newman EM. Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. Leuk Lymphoma. 2020 Feb; 61 (2):309-317 Epub 2019 Oct 16
    View PubMed
  91. Parrondo RD, Ailawadhi S, Sher T, Chanan-Khan AA, Roy V. Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies. JCO Oncol Pract. 2020 Feb; 16 (2):56-66
    View PubMed
  92. Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, Casey G, Stevens VL, Kittles R, Goodman PJ, Diver WR, Hennis A, Nemesure B, Klein EA, Rybicki BA, Stanford JL, Witte JS, Signorello L, John EM, Bernstein L, Stroup AM, Stephens OW, Zangari M, Van Rhee F, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Ingles SA, Press MF, Carpten JD, Chanock SJ, Mehta J, Colditz GA, Wolf J, Martin TG, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Anderson KC, Le Marchand L, Auclair D, Chiu BC, Ziv E, Stram D, Vij R, Bernal-Mizrachi L, Morgan GJ, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti DV, Haiman CA, Cozen W. A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Adv. 2020 Jan 14; 4 (1):181-190
    View PubMed
  93. Parrondo RD, Roy V, Sher T, Alegria V, Chanan-Khan AA, Ailawadhi S. Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review. Case Rep Hematol. 2020; 2020:4360926 Epub 2020 Feb 18
    View PubMed
  94. Ailawadhi S, Jagannath S, Narang M, Rifkin RM, Terebelo HR, Toomey K, Durie BGM, Hardin JW, Gasparetto CJ, Wagner L, Omel JL, Kumar V, Yue L, Kitali A, Agarwal A, Abonour R, Connect MM Registry Investigators. Connect MM Registry as a national reference for United States multiple myeloma patients. Cancer Med. 2020 Jan; 9 (1):35-42 Epub 2019 Nov 07
    View PubMed
  95. Advani P, Paulus A, Ailawadhi S. Updates in prognostication and treatment of Waldenstrom's macroglobulinemia. Hematol Oncol Stem Cell Ther. 2019 Dec; 12 (4):179-188 Epub 2019 May 28
    View PubMed
  96. Ailawadhi S, Parikh K, Abouzaid S, Zhou Z, Tang W, Clancy Z, Cheung C, Zhou ZY, Xie J. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis. Blood Adv. 2019 Oct 22; 3 (20):2986-2994
    View PubMed
  97. Aulakh S, DeDeo MR, Free J, Rosenfeld SS, Quinones-Hinojosa A, Paulus A, Manna A, Manochakian R, Chanan-Khan AA, Ailawadhi S. Survival trends in glioblastoma and association with treating facility volume. J Clin Neurosci. 2019 Oct; 68:271-274 Epub 2019 May 24
    View PubMed
  98. Ailawadhi S, Azzouqa AG, Hodge D, Cochuyt J, Jani P, Ahmed S, Sher T, Roy V, Ailawadhi M, Alegria VR, Manochakian R, Vishnu P, Grover A, Abdulazeez MF, Paulus A, Chanan-Khan A. Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities. Clin Lymphoma Myeloma Leuk. 2019 Oct; 19 (10):619-623 Epub 2019 June 26
    View PubMed
  99. Kumar V, Ailawadhi S, Bojanini L, Mehta A, Biswas S, Sher T, Roy V, Vishnu P, Marin-Acevedo J, Alegria VR, Paulus A, Aulakh S, Iqbal M, Manochakian R, Tan W, Chanan-Khan A, Ailawadhi M. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J. 2019 Sep 30; 9 (10):75 Epub 2019 Sept 30
    View PubMed
  100. Osagiede O, Spaulding AC, Frank RD, Merchea A, Uitti R, Ailawadhi S, Kelley S, Colibaseanu D. Predictors of palliative treatment in stage IV colorectal cancer. Am J Surg. 2019 Sep; 218 (3):514-520 Epub 2018 Dec 14
    View PubMed
  101. Ailawadhi S, Sher T, Azzouqa AG, Meghji Z, Jain T, Jani P, Ahmed S, Diehl N, Roy V, Shah V, Hodge D, Ailawadhi M, Alegria VR, Paulus A, Chanan-Khan A, Fonseca R. Monoclonal antibody utilization characteristics in patients with multiple myeloma. Anticancer Drugs. 2019 Sep; 30 (8):859-865
    View PubMed
  102. Manna A, Aulakh S, Jani P, Ahmed S, Akhtar S, Coignet M, Heckman M, Meghji Z, Bhatia K, Sharma A, Sher T, Alegria V, Malavasi F, Chini EN, Chanan-Khan A, Ailawadhi S, Paulus A. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2019 Jul 1; 25 (13):3974-3985 Epub 2019 Apr 02
    View PubMed
  103. Jagannath S, Heffner LT Jr, Ailawadhi S, Munshi NC, Zimmerman TM, Rosenblatt J, Lonial S, Chanan-Khan A, Ruehle M, Rharbaoui F, Haeder T, Wartenberg-Demand A, Anderson KC. Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 Jun; 19 (6):372-380 Epub 2019 Feb 21
    View PubMed
  104. Ailawadhi S, Dholaria BR, Khurana S, Sher T, Alegria V, Paulus A, Ailawadhi M, Mehta A, Chanan-Khan A, Roy V. Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma. Br J Haematol. 2019 Apr; 185 (2):347-350 Epub 2018 July 05
    View PubMed
  105. Ailawadhi S, DerSarkissian M, Duh MS, Lafeuille MH, Posner G, Ralston S, Zagadailov E, Ba-Mancini A, Rifkin R. Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma. Clin Ther. 2019 Mar; 41 (3):477-493.e7 Epub 2019 Feb 14
    View PubMed
  106. Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant. 2019 Mar; 54 (3):353-367 Epub 2018 July 09
    View PubMed
  107. Stewart AK, Krishnan AY, Singhal S, Boccia RV, Patel MR, Niesvizky R, Chanan-Khan AA, Ailawadhi S, Brumm J, Mundt KE, Hong K, McBride J, Shon-Nguyen Q, Xiao Y, Ramakrishnan V, Polson AG, Samineni D, Leipold D, Humke EW, McClellan JS, Berdeja JG. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood Cancer J. 2019 Feb 4; 9 (2):17 Epub 2019 Feb 04
    View PubMed
  108. Khurana S, Ahmed S, Alegria VR, Aulakh S, Ailawadhi M, Singh A, Chanan-Khan A, Ailawadhi S. Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia. SAGE Open Med Case Rep. 2019; 7:2050313X18823917 Epub 2019 Jan 16
    View PubMed
  109. Ganguly S, Mailankody S, Ailawadhi S. Many Shades of Disparities in Myeloma Care. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:519-529 Epub 2019 May 17
    View PubMed
  110. Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 Jan; 19 (1):9-22 Epub 2018 Sept 05
    View PubMed
  111. Ailawadhi S, Kelly KR, Vescio RA, Jagannath S, Wolf J, Gharibo M, Sher T, Bojanini L, Kirby M, Chanan-Khan A. A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 Jan; 19 (1):29-34 Epub 2018 Sept 05
    View PubMed
  112. Mody K, Antwi SO, Hodge DO, Ailawadhi S, Roberts L, Bekaii-Saab T. A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin. J Gastrointest Oncol. 2018 Dec; 9 (6):1063-1073
    View PubMed
  113. Lou Y, Dholaria B, Soyano A, Hodge D, Cochuyt J, Manochakian R, Ko SJ, Thomas M, Johnson MM, Patel NM, Miller RC, Adjei AA, Ailawadhi S. Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Med. 2018 Oct; 7 (10):4932-4942 Epub 2018 Sept 02
    View PubMed
  114. Paulus A, Manna A, Akhtar S, Paulus SM, Sharma M, Coignet MV, Jiang L, Roy V, Witzig TE, Ansell SM, Allan J, Furman R, Aulakh S, Manochakian R, Ailawadhi S, Chanan-Khan AA, Sher T. Targeting CD38 with daratumumab is lethal to Waldenstrom macroglobulinaemia cells. Br J Haematol. 2018 Oct; 183 (2):196-211 Epub 2018 Aug 06
    View PubMed
  115. Ahmed S, Jani P, Yamani MH, Ailawadhi S, Alegria VR, Ailawadhi M. Marantic Endocarditis Associated With T-Cell Large Granular Lymphocytic Leukemia: First Report of Its Occurrence With a Lymphoproliferative Malignancy in Adults. J Oncol Pract. 2018 Oct; 14 (10):625-627 Epub 2018 Sept 17
    View PubMed
  116. Colibaseanu DT, Osagiede O, Spaulding AC, Frank RD, Merchea A, Mathis KL, Parker AS, Ailawadhi S. The Determinants of Palliative Care Use in Patients With Colorectal Cancer: A National Study. Am J Hosp Palliat Care. 2018 Oct; 35 (10):1295-1303 Epub 2018 Mar 26
    View PubMed
  117. Abonour R, Rifkin RM, Gasparetto C, Toomey K, Durie BGM, Hardin JW, Terebelo HR, Jagannath S, Narang M, Ailawadhi S, Srinivasan S, Kitali A, Agarwal A, Wagner L. Impact of initial treatment (tx) on HRQoL and outcomes in patients (pts) with newly diagnosed multiple myeloma (NDMM) without intent for immediate transplant (SCT): Results from the Connect(R) MM registry. Ann Oncol. 2018 Oct; 29 Suppl 8:viii360
    View PubMed
  118. Kumar V, Garg M, Chandra AB, Mayorga VS, Ahmed S, Ailawadhi S. Trends in the Risks of Secondary Cancers in Patients With Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2018 Sep; 18 (9):576-589.e1 Epub 2018 May 30
    View PubMed
  119. Duma N, Azam T, Riaz IB, Gonzalez-Velez M, Ailawadhi S, Go R. Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials. Oncologist. 2018 Sep; 23 (9):1076-1078 Epub 2018 Apr 26
    View PubMed
  120. Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, King RL, Koehler AB, Reeder CB, Buadi FK, Dispenzieri A, Lacy MQ, Dingli D, Witzig TE, Go RS, Gonsalves WI, Kourelis T, Warsame R, Leung N, Habermann TM, Hayman S, Lin Y, Kyle RA, Rajkumar SV, Gertz MA, Kapoor P. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia. Ann Hematol. 2018 Aug; 97 (8):1417-1425 Epub 2018 Apr 03
    View PubMed
  121. Ailawadhi S, Jacobus S, Sexton R, Stewart AK, Dispenzieri A, Hussein MA, Zonder JA, Crowley J, Hoering A, Barlogie B, Orlowski RZ, Rajkumar SV. Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J. 2018 Jul 6; 8 (7):67 Epub 2018 July 06
    View PubMed
  122. Ailawadhi S, Panjabi S, Campioni M, Majer I, Jakubowiak A. Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma. J Manag Care Spec Pharm 2018 Jul; 24 (7):711-712
    View PubMed
  123. Osagiede O, Colibaseanu DT, Spaulding AC, Frank RD, Merchea A, Kelley SR, Uitti RJ, Ailawadhi S. Palliative Care Use Among Patients With Solid Cancer Tumors: A National Cancer Data Base Study. J Palliat Care. 2018 Jul; 33 (3):149-158 Epub 2018 May 29
    View PubMed
  124. Jani P, Vissing MB, Ahmed S, Sluzevich JC, Aulakh S, Alegria V, Ailawadhi M, Chanan-Khan A, Ailawadhi S. Ibrutinib for the Management of Schnitzler Syndrome: A Novel Therapy for a Rare Condition. J Oncol Pract. 2018 Jun; 14 (6):387-388 Epub 2018 Mar 20
    View PubMed
  125. Niazi S, Frank RD, Sharma M, Roy V, Ames S, Rummans T, Spaulding A, Sher T, Ailawadhi M, Bhatia K, Ahmed S, Tan W, Chanan-Khan A, Ailawadhi S. Impact of psychiatric comorbidities on health care utilization and cost of care in multiple myeloma. Blood Adv. 2018 May 22; 2 (10):1120-1128
    View PubMed
  126. Ailawadhi S, Frank RD, Sharma M, Menghani R, Temkit M, Paulus S, Khera N, Hashmi S, Advani P, Swaika A, Paulus A, Aslam N, Sher T, Roy V, Colon-Otero G, Chanan-Khan A. Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. Cancer. 2018 Apr 15; 124 (8):1710-1721 Epub 2018 Jan 23
    View PubMed
  127. Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. Ann Intern Med. 2018 Apr 3; 168 (7):461-470 Epub 2018 Feb 20
    View PubMed
  128. Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. Lancet Haematol. 2018 Apr; 5 (4):e170-e180 Epub 2018 Mar 14
    View PubMed
  129. Shreders AJ, Niazi SK, Hodge DO, Chimato NT, Kureti M, Kirla N, Agrawal A, Swaika A, Gustetic E, Foster R, Nelson KA, Jani P, Chanan-Khan AA, Ailawadhi S. Correlation of sociodemographic and clinical parameters with depression and distress in patients with hematologic malignancies. Ann Hematol. 2018 Mar; 97 (3):519-528 Epub 2017 Dec 07
    View PubMed
  130. Ailawadhi S, Mikhael JR, LaPlant BR, Laumann KM, Kumar S, Roy V, Dingli D, Bergsagel PL, Buadi FK, Rajkumar SV, Fonseca R, Gertz MA, Kapoor P, Sher T, Hayman SR, Stewart AK, Dispenzieri A, Kyle RA, Gonsalves WI, Reeder CB, Lin Y, Go RS, Leung N, Kourelis T, Lust JA, Russell SJ, Chanan-Khan AA, Lacy MQ. Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial. Leukemia. 2018 Mar; 32 (3):719-728 Epub 2017 Sept 01
    View PubMed
  131. Swaika A, Frank RD, Yang D, Finn LE, Jiang L, Advani P, Chanan-Khan AA, Ailawadhi S, Foran JM. Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes. Cancer Med. 2018 Feb; 7 (2):499-507 Epub 2017 Dec 28
    View PubMed
  132. Huang YL, Bryce AH, Culbertson T, Connor SL, Looker SA, Altman KM, Collins JG, Stellner W, McWilliams RR, Moreno-Aspitia A, Ailawadhi S, Mesa RA. Alternative Outpatient Chemotherapy Scheduling Method to Improve Patient Service Quality and Nurse Satisfaction. J Oncol Pract. 2018 Feb; 14 (2):e82-e91 Epub 2017 Dec 22
    View PubMed
  133. Jakubowiak AJ, Houisse I, Majer I, Benedict A, Campioni M, Panjabi S, Ailawadhi S. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. Expert Rev Hematol. 2017 Dec; 10 (12):1107-1119
    View PubMed
  134. Ailawadhi S, Frank RD, Advani P, Swaika A, Temkit M, Menghani R, Sharma M, Meghji Z, Paulus S, Khera N, Hashmi SK, Paulus A, Kakar TS, Hodge DO, Colibaseanu DT, Vizzini MR, Roy V, Colon-Otero G, Chanan-Khan AA. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis. Cancer Med. 2017 Dec; 6 (12):2876-2885 Epub 2017 Nov 03
    View PubMed
  135. Pelligra CG, Parikh K, Guo S, Chandler C, Mouro J, Abouzaid S, Ailawadhi S. Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States. Clin Ther. 2017 Oct; 39 (10):1986-2005.e5 Epub 2017 Sept 28
    View PubMed
  136. Paludo J, Abeykoon JP, Kumar S, Shreders A, Ailawadhi S, Gertz MA, Kourelis T, King RL, Reeder CB, Leung N, Kyle RA, Buadi FK, Habermann TM, Dingli D, Witzig TE, Dispenzieri A, Lacy MQ, Go RS, Lin Y, Gonsalves WI, Warsame R, Lust JA, Rajkumar SV, Ansell SM, Kapoor P. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naive patients with Waldenstrom macroglobulinemia. Br J Haematol. 2017 Oct; 179 (1):98-105 Epub 2017 Aug 08
    View PubMed
  137. Paludo J, Mikhael JR, LaPlant BR, Halvorson AE, Kumar S, Gertz MA, Hayman SR, Buadi FK, Dispenzieri A, Lust JA, Kapoor P, Leung N, Russell SJ, Dingli D, Go RS, Lin Y, Gonsalves WI, Fonseca R, Bergsagel PL, Roy V, Sher T, Chanan-Khan AA, Ailawadhi S, Stewart AK, Reeder CB, Richardson PG, Rajkumar SV, Lacy MQ. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. Blood. 2017 Sep 7; 130 (10):1198-1204 Epub 2017 July 06
    View PubMed
  138. Kapoor P, Ansell SM, Fonseca R, Chanan-Khan A, Kyle RA, Kumar SK, Mikhael JR, Witzig TE, Mauermann M, Dispenzieri A, Ailawadhi S, Stewart AK, Lacy MQ, Thompson CA, Buadi FK, Dingli D, Morice WG, Go RS, Jevremovic D, Sher T, King RL, Braggio E, Novak A, Roy V, Ketterling RP, Greipp PT, Grogan M, Micallef IN, Bergsagel PL, Colgan JP, Leung N, Gonsalves WI, Lin Y, Inwards DJ, Hayman SR, Nowakowski GS, Johnston PB, Russell SJ, Markovic SN, Zeldenrust SR, Hwa YL, Lust JA, Porrata LF, Habermann TM, Rajkumar SV, Gertz MA, Reeder CB. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol. 2017 Sep 1; 3 (9):1257-1265
    View PubMed
  139. Ailawadhi S, Bhatia K, Aulakh S, Meghji Z, Chanan-Khan A. Equal Treatment and Outcomes for Everyone with Multiple Myeloma: Are We There Yet? Curr Hematol Malig Rep. 2017 Aug; 12 (4):309-316
    View PubMed
  140. Paulus A, Akhtar S, Yousaf H, Manna A, Paulus SM, Bashir Y, Caulfield TR, Kuranz-Blake M, Chitta K, Wang X, Asmann Y, Hudec R, Springer W, Ailawadhi S, Chanan-Khan A. Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J. 2017 May 26; 7 (5):e565
    View PubMed
  141. Gautam A, Sahu KK, Alamgir A, Siddiqi I, Ailawadhi S. Extramedullary Solitary Plasmacytoma: Demonstrating the Role of (18)F-FDG PET Imaging. J Clin Diagn Res. 2017 Apr; 11 (4):XD01-XD03 Epub 2017 Apr 01
    View PubMed
  142. Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc. 2017 Apr; 92 (4):578-598 Epub 2017 Mar 11
    View PubMed
  143. Sahu KK, Gautam A, Ailawadhi S. Re: FDG PET/CT Findings of Intracardiac Myeloid Sarcoma. Clin Nucl Med 2017 Mar; 42 (3):242-245
    View PubMed
  144. Gautam A, Jalali GK, Sahu KK, Deo P, Ailawadhi S. Cardiac Myeloid Sarcoma: Review of Literature. J Clin Diagn Res. 2017 Mar; 11 (3):XE01-XE04 Epub 2017 Mar 01
    View PubMed
  145. Colon-Otero G, Van Wier SA, Ahmann GJ, Braggio E, Albertie ML, Weis JA, Ailawadhi S, Cerhan JR, Vishnu P, Jorgensen MS, Foran JM, Thomas CS, Fonseca R. Prevalence of BCL-2/J(H) Translocation in Healthy African Americans. Ann Hematol. 2017 Jan; 96 (1):51-55 Epub 2016 Oct 12
    View PubMed
  146. Ailawadhi S, Akard LP, Miller CB, Jillella A, DeAngelo DJ, Ericson SG, Lin F, Warsi G, Radich J. Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib. Ther Adv Hematol. 2017 Jan; 8 (1):3-12 Epub 2016 Nov 24
    View PubMed
  147. Egan JB, Marks DL, Hogenson TL, Vrabel AM, Sigafoos AN, Tolosa EJ, Carr RM, Safgren SL, Hesles EE, Almada LL, Romecin-Duran PA, Iguchi E, Ala'Aldeen A, Kocher JA, Oliver GR, Prodduturi N, Mead DW, Hossain A, Huneke NE, Tagtow CM, Ailawadhi S, Ansell SM, Banck MS, Bryce AH, Carballido EM, Chanan-Khan AA, Curtis KK, Resnik E, Gawryletz CD, Go RS, Halfdanarson TR, Ho TH, Joseph RW, Kapoor P, Mansfield AS, Meurice N, Nageswara Rao AA, Nowakowski GS, Pardanani A, Parikh SA, Cheville JC, Feldman AL, Ramanathan RK, Robinson SI, Tibes R, Finnes HD, McCormick JB, McWilliams RR, Jatoi A, Patnaik MM, Silva AC, Wieben ED, McAllister TM, Rumilla KM, Kerr SE, Lazaridis KN, Farrugia G, Stewart AK, Clark KJ, Kennedy EJ, Klee EW, Borad MJ, Fernandez-Zapico ME. Molecular Modeling and Functional Analysis of Exome Sequencing-Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma. JCO Precis Oncol. 2017; 2017 Epub 2017 Aug 01
    View PubMed
  148. Waddle M, Irvin M, Gupta E, Gibbs M, Kakar TS, Gannon NA, Arthurs JR, Fischer DL, Ailawadhi S. Acute Disseminated Intravascular Coagulation after Oxaliplatin Infusion. Chemotherapy. 2017; 62 (5):295-300 Epub 2017 May 16
    View PubMed
  149. Chesi M, Mirza NN, Garbitt VM, Sharik ME, Dueck AC, Asmann YW, Akhmetzyanova I, Kosiorek HE, Calcinotto A, Riggs DL, Keane N, Ahmann GJ, Morrison KM, Fonseca R, Lacy MQ, Dingli D, Kumar SK, Ailawadhi S, Dispenzieri A, Buadi F, Gertz MA, Reeder CB, Lin Y, Chanan-Khan AA, Stewart AK, Fooksman D, Bergsagel PL. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat Med. 2016 Dec; 22 (12):1411-1420 Epub 2016 Nov 14
    View PubMed
  150. Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiol Biomarkers Prev. 2016 Dec; 25 (12):1609-1618 Epub 2016 Sept 01
    View PubMed
  151. Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood. 2016 Nov 17; 128 (20):2415-2422 Epub 2016 Oct 04
    View PubMed
  152. Paulus A, Akhtar S, Caulfield TR, Samuel K, Yousaf H, Bashir Y, Paulus SM, Tran D, Hudec R, Cogen D, Jiang J, Edenfield B, Novak A, Ansell SM, Witzig T, Martin P, Coleman M, Roy V, Ailawadhi S, Chitta K, Linder S, Chanan-Khan A. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. Blood Cancer J. 2016 Nov 4; 6 (11):e492 Epub 2016 Nov 04
    View PubMed
  153. Ailawadhi S, Paulus A, Chanan-Khan A. Preclinical models of Waldenstrom's macroglobulinemia and drug resistance. Best Pract Res Clin Haematol. 2016 Jun; 29 (2):169-178 Epub 2016 Sept 04
    View PubMed
  154. Paulus A, Ailawadhi S, Chanan-Khan A. Novel therapeutic targets in Waldenstrom macroglobulinemia. Best Pract Res Clin Haematol. 2016 Jun; 29 (2):216-228 Epub 2016 Sept 07
    View PubMed
  155. Pawlyn C, Gay F, Larocca A, Roy V, Ailawadhi S. Nuances in the Management of Older People With Multiple Myeloma. Curr Hematol Malig Rep. 2016 Jun; 11 (3):241-51
    View PubMed
  156. Ailawadhi S, Advani P, Yang D, Ghosh R, Swaika A, Roy V, Foran J, Colon-Otero G, Chanan-Khan A. Impact of access to NCI- and NCCN-designated cancer centers on outcomes for multiple myeloma patients: A SEER registry analysis. Cancer. 2016 Feb 15; 122 (4):618-25 Epub 2015 Nov 13
    View PubMed
  157. Swaika A, Boczek NJ, Sood N, Guthrie K, Klee EW, Agrawal A, Dimberg EL, Ailawadhi S. Whole Exome Sequencing Leading to the Diagnosis of Dysferlinopathy with a Novel Missense Mutation (c.959G>C). Case Rep Genet. 2016; 2016:9280812 Epub 2016 Apr 19
    View PubMed
  158. Shreders A, Niazi S, Hodge D, Chimato N, Agarwal A, Gustetic E, Hammond WA, Dholaria BR, Ailawadhi S. Universal screening for depression in cancer patients and its impact on management patterns Journal of Clinical Oncology. 2016; 34 (26 Suppl):232
  159. Crozier JA, Sher T, Yang D, Swaika A, Foran J, Ghosh R, Tun H, Colon-Otero G, Kelly K, Chanan-Khan A, Ailawadhi S. Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review. Clin Lymphoma Myeloma Leuk. 2015 Oct; 15 (10):578-85 Epub 2015 June 19
    View PubMed
  160. Angell TE, Swaika A, Sood N, Goldfarb M, Siddiqi I, Ailawadhi S. Localized LECT2 amyloidosis of the adrenal gland with coexisting MGUS: a diagnostic challenge. Ann Hematol. 2015 Sep; 94: (9)1603-4.
    View PubMed
  161. Dispenzieri A, Buadi F, Kumar SK, Reeder CB, Sher T, Lacy MQ, Kyle RA, Mikhael JR, Roy V, Leung N, Grogan M, Kapoor P, Lust JA, Dingli D, Go RS, Hwa YL, Hayman SR, Fonseca R, Ailawadhi S, Bergsagel PL, Chanan-Khan A, Rajkumar SV, Russell SJ, Stewart K, Zeldenrust SR, Gertz MA. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement. Mayo Clin Proc. 2015 Aug; 90(8):1054-81.
    View PubMed
  162. Swaika A, Sood N, Menke DM, Jha A, Ailawadhi S. Langerhans Cell Sarcoma: Treatment with Dose-adjusted EPOCH Chemo Open Access.2015;4:(3):155.
  163. Chitta K, Paulus A, Akhtar S, Blake MK, Caulfield TR, Novak AJ, Ansell SM, Advani P, Ailawadhi S, Sher T, Linder S, Chanan-Khan A. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells. Br J Haematol. 2015 May; 169(3):377-90. Epub 2015 Feb 17.
    View PubMed
  164. Paulus A, Chitta KS, Wallace PK, Advani PP, Akhtar S, Kuranz-Blake M, Ailawadhi S, Chanan-Khan AA. Immunophenotyping of Waldenströms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications. PLoS One. 2015; 10(4):e0122338. Epub 2015 Apr 08.
    View PubMed
  165. Ailawadhi S. The changing face of multiple myeloma American Journal of Hematology/Oncology. 2015; 11 (10):21-5
  166. Chitta K, Paulus A, Caulfield TR, Akhtar S, Blake MK, Ailawadhi S, Knight J, Heckman MG, Pinkerton A, Chanan-Khan A. Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia. Blood Cancer J. 2014 Nov 07; 4:e260.
    View PubMed
  167. Swaika A, Ailawadhi S, Menke DM. Disseminated histoplasmosis in a renal transplant patient. Int J Hematol. 2014 Oct; 100(4):315-6. Epub 2014 Jul 27.
    View PubMed
  168. Ailawadhi S, Swaika A, Razavi P, Yang D, Chanan-Khan A. Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups. Blood Cancer J. 2014 Sep 5; 4:e243 Epub 2014 Sept 05
    View PubMed
  169. Siddiqi IN, Ailawadhi S, Huang Q, Shibata RK, Kang H, Shibata D. Deep Sequencing Reveals Lack of a Clonal Relationship Between a Metachronous Classical Hodgkin and Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2014 Jan 04.
    View PubMed
  170. Kim MY, Sposto R, Swaika A, Asano H, Alamgir A, Chanan-Khan A, Ailawadhi S. Pharmacoeconomic implications of lenalidomide maintenance therapy in multiple myeloma. Oncology. 2014; 87(4):224-31.
    View PubMed
  171. Ailawadhi S, Kardosh A, Yang D, Cozen W, Patel G, Alamgir MA, Chanan-Khan AA. Outcome disparities among ethnic subgroups of Waldenstrom's macroglobulinemia: a population-based study. Oncology. 2014; 86 (5-6):253-62 Epub 2014 June 04
    View PubMed
  172. Chitta KS, Paulus A, Ailawadhi S, Foster BA, Moser MT, Starostik P, Masood A, Sher T, Miller KC, Iancu DM, Conroy J, Nowak NJ, Sait SN, Personett DA, Coleman M, Furman RR, Martin P, Ansell SM, Lee K, Chanan-Khan AA. Development and characterization of a novel human Waldenstrom macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenstrom Macroglobulinemia 1. Leuk Lymphoma. 2013 Feb; 54 (2):387-96 Epub 2012 Aug 27
    View PubMed
  173. Guiang KM, Cantey P, Mongomery SP, Ailawadhi S, Qvarnstrom Y, Price T, Blodget E. Reactivation of Chagas disease in a bone marrow transplant patient: Case report and review of screening and management. Transpl Infet Dis. 2013; 15(6):E264-7.
  174. Razavi P, Rand KA, Cozen W, Chanan-Khan A, Usmani S, Ailawadhi S. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer J. 2013; 3:e121. Epub 2013 Jun 28
    View PubMed
  175. Ailawadhi S, Aldoss IT, Yang D, Razavi P, Cozen W, Sher T, Chanan-Khan A. Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups. Br J Haematol. 2012 Jul; 158(1):91-8. Epub 2012 Apr 26.
    View PubMed
  176. Ailawadhi S, Miecznikowski J, Gaile DP, Wang D, Sher T, Mulligan G, Bryant B, Wilding GE, Mashtare T, Stein L, Masood A, Neuwirth R, Lee KP, Chanan-Khan A. Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012 Jun; 53(6):1174-82. Epub 2011 Dec 6
    View PubMed
  177. Masood A, Chitta K, Paulus A, Khan AN, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I, Lee KP, Chanan-Khan A. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Br J Haematol. 2012 Apr; 157: (1)59-66.
    View PubMed
  178. Sher T, Ailawadhi S, Miller KC, Manfredi D, Wood M, Tan W, Wilding G, Czuczman MS, Hernandez-Ilizaliturri FJ, Hong F, Sood R, Soniwala S, Lawrence W, Jamshed S, Masood A, Iancu D, Lee K, Chanan-Khan A. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol. 2011 Jul; 154(1):104-10. Epub 2011 May 09.
    View PubMed
  179. Ailawadhi S, Abdelhalim AN, Derby L, Mashtare TL, Miller KC, Wilding GE, Alberico RA, Gottlieb R, Klippenstein DL, Lee K, Chanan-Khan AA. Extent of disease burden determined with magnetic resonance imaging of the bone marrow is predictive of survival outcome in patients with multiple myeloma. Cancer. 2010 Jan 1; 116(1):84-92.
    View PubMed
  180. Chanan-Khan A, Miller KC, Musial L, Padmanabhan S, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein ZP, Barcos M, Patel M, Iancu D, Lee K, Czuczman MS. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma. 2009 Jul; 50(7):1096-101.
    View PubMed
  181. Ailawadhi S, Derby L, Natarajan R, Fetterly G, Reid M, Ramnath N. Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experience. Oncology. 2009; 76(2):85-90. Epub 2008 Dec 20
    View PubMed
  182. Donthireddy KR, Ailawadhi S, Nasser E, Schiff MD, Nwogu CE, Nava HR, Javle MM. Malignant gastroparesis: pathogenesis and management of an underrecognized disorder. J Support Oncol. 2007 Sep; 5(8):355-63.
    View PubMed
  183. Ailawadhi S, Nagase H, Khoury T, Yu J, Tan D, Black J, Brattain M, Javle M. Intestinal trefoil factor (TFF-3) and extracellular signal-regulated kinase (ERK) in cholangiocarcinoma. Hepatogastroenterology. 2007 Jul-Aug; 54(77):1339-44.
    View PubMed
  184. Ailawadhi S, Sung KW, Carlson LA, Baer MR. Serotonin syndrome caused by interaction between citalopram and fentanyl. J Clin Pharm Ther. 2007 Apr; 32(2):199-202.
    View PubMed
  185. Javle M, Ailawadhi S, Yang GY, Nwogu CE, Schiff MD, Nava HR. Palliation of malignant dysphagia in esophageal cancer: a literature-based review. J Support Oncol. 2006 Sep; 4(8):365-73, 379.
    View PubMed
  186. Ailawadhi S, Sunga A, Rajput A, Yang GY, Smith J, Fakih M. Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology. 2006; 70(1):49-53. Epub 2006 Jan 27.
    View PubMed